185 Pityriasis lichenoides et varioliformis acuta Alex Milligan and Graham A. Johnston Evidence Levels: A Double-blind study B Clinical trial ≥ 20 subjects C Clinical trial < 20 subjects D Series ≥ 5 subjects E Anecdotal case reports Pityriasis lichenoides et varioliformis acuta (PLEVA) is an eruption of small, erythematous papules which become vesicular and hemorrhagic. Some ulcerate and necrose, leaving pitted scars. The name refers to the morphology not the duration of the condition, because a significant proportion of cases regress with or without treatment, only to recur. Patients should be warned that relapse is common and that recurrent courses of therapy may be required. Febrile ulceronecrotic Mucha–Habermann disease is a rare and severe form of PLEVA characterized by an abrupt onset of an ulceronecrotic eruption associated with a high fever and systemic symptoms. Management strategy There are only a handful of controlled trials for this condition and large series are rare. In many therapeutic trials PLEVA is often grouped together with pityriasis lichenoides chronica and management strategies are therefore often similar or interchangeable. Although a ‘wait and see’ approach is justifiable in infants, children should be given a 6-week course of high-dose erythromycin. Tetracycline should not be given because of its effects on dentition. Second-line therapy in children, and possibly first-line in adults, is either UV light or psoralen plus UVA (PUVA) because the only comparative study has shown this to be more effective. Topical corticosteroids are only reported anecdotally in textbooks rather than in studies. They are used with antihistamines to reduce pruritus, but have no reported effect on disease course. In more extensive or symptomatic disease low-dose methotrexate is useful, and systemic corticosteroids or cyclosporine have also been used. Some authors have suggested that combination therapy (e.g., erythromycin and PUVA or methotrexate and PUVA) is effective, especially in the rare, febrile ulceronecrotic variant of Mucha–Habermann disease. Specific investigations Consider skin biopsy A diagnostic skin biopsy is unnecessary in clinically obvious cases, but may be useful to exclude lymphomatoid papulosis or before commencing aggressive systemic therapy. An infective etiology for PLEVA is suggested by reports of clustering of cases, resolution following tonsillectomy, and occurrence in five members of a family. Case reports exist associating PLEVA with parvovirus, adenovirus in the urine, staphylococci from throat cultures, Epstein–Barr virus, toxoplasmosis, and HIV. No organism has been cultured from lesional skin and, unless there are clinical signs of infection, routine investigation for an infective agent does not appear to be useful. Pityriasis lichenoides: a cytotoxic T-cell-mediated skin disorder. Evidence of human parvovirus B19 DNA in nine cases. Tomasini D, Tomasini CF, Cerri A, Sangalli G, Palmedo G, Hantschke M, et al. J Cutan Pathol 2004; 31: 531–8. This study suggests that pityriasis lichenoides is mediated by a cytotoxic T-cell effector population. The identification of parvovirus B19 DNA in nine cases may be interpreted ambiguously. Pityriasis lichenoides et varioliformis acuta and group-A beta hemolytic streptococcal infection. English JC III, Collins M, Bryant-Bruce C. Int J Dermatol 1995; 34: 642–4. Biopsy-proven PLEVA in association with carriage of Gram-positive cocci cleared with ciprofloxacin in a 35-year-old woman. An identical eruption in her husband, who was found to have group A β-hemolytic streptococcus from a skin swab, cleared with erythromycin. Pityriasis lichenoides and acquired toxoplasmosis. Rongioletti F, Delmonte S, Rebora A. Int J Dermatol 1999; 38: 367–76. Biopsy-proven PLEVA in a patient with serology indicating acute toxoplasmosis failed to respond to azithromycin, but cleared with spiramycin followed by trimethoprim–sulfamethoxazole. First-line therapies Oral erythromycin C Pityriasis lichenoides in childhood: a retrospective review of 124 patients. Ersoy-Evans S, Greco MF, Mancini AJ, Subasi N, Paller AS. J Am Acad Dermatol 2007; 56: 205–10. This was a retrospective study of 124 children, 71 of whom had PLEVA. The disease was recurrent in 77%. Erythromycin was given to 79.7% of the affected children and 66.6% of these showed at least a partial response. Only gold members can continue reading. Log In or Register to continue Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window) Related Related posts: Cat scratch disease Hemangiomas Tinea capitis Necrolytic migratory erythema Nevoid basal cell carcinoma syndrome Rocky Mountain spotted fever and other rickettsial infections Stay updated, free articles. Join our Telegram channel Join Tags: Treatment of Skin Disease Comprehensive Therapeutic Strategies Aug 7, 2016 | Posted by admin in Dermatology | Comments Off on Pityriasis lichenoides et varioliformis acuta Full access? Get Clinical Tree Get Clinical Tree app for offline access Get Clinical Tree app for offline access
185 Pityriasis lichenoides et varioliformis acuta Alex Milligan and Graham A. Johnston Evidence Levels: A Double-blind study B Clinical trial ≥ 20 subjects C Clinical trial < 20 subjects D Series ≥ 5 subjects E Anecdotal case reports Pityriasis lichenoides et varioliformis acuta (PLEVA) is an eruption of small, erythematous papules which become vesicular and hemorrhagic. Some ulcerate and necrose, leaving pitted scars. The name refers to the morphology not the duration of the condition, because a significant proportion of cases regress with or without treatment, only to recur. Patients should be warned that relapse is common and that recurrent courses of therapy may be required. Febrile ulceronecrotic Mucha–Habermann disease is a rare and severe form of PLEVA characterized by an abrupt onset of an ulceronecrotic eruption associated with a high fever and systemic symptoms. Management strategy There are only a handful of controlled trials for this condition and large series are rare. In many therapeutic trials PLEVA is often grouped together with pityriasis lichenoides chronica and management strategies are therefore often similar or interchangeable. Although a ‘wait and see’ approach is justifiable in infants, children should be given a 6-week course of high-dose erythromycin. Tetracycline should not be given because of its effects on dentition. Second-line therapy in children, and possibly first-line in adults, is either UV light or psoralen plus UVA (PUVA) because the only comparative study has shown this to be more effective. Topical corticosteroids are only reported anecdotally in textbooks rather than in studies. They are used with antihistamines to reduce pruritus, but have no reported effect on disease course. In more extensive or symptomatic disease low-dose methotrexate is useful, and systemic corticosteroids or cyclosporine have also been used. Some authors have suggested that combination therapy (e.g., erythromycin and PUVA or methotrexate and PUVA) is effective, especially in the rare, febrile ulceronecrotic variant of Mucha–Habermann disease. Specific investigations Consider skin biopsy A diagnostic skin biopsy is unnecessary in clinically obvious cases, but may be useful to exclude lymphomatoid papulosis or before commencing aggressive systemic therapy. An infective etiology for PLEVA is suggested by reports of clustering of cases, resolution following tonsillectomy, and occurrence in five members of a family. Case reports exist associating PLEVA with parvovirus, adenovirus in the urine, staphylococci from throat cultures, Epstein–Barr virus, toxoplasmosis, and HIV. No organism has been cultured from lesional skin and, unless there are clinical signs of infection, routine investigation for an infective agent does not appear to be useful. Pityriasis lichenoides: a cytotoxic T-cell-mediated skin disorder. Evidence of human parvovirus B19 DNA in nine cases. Tomasini D, Tomasini CF, Cerri A, Sangalli G, Palmedo G, Hantschke M, et al. J Cutan Pathol 2004; 31: 531–8. This study suggests that pityriasis lichenoides is mediated by a cytotoxic T-cell effector population. The identification of parvovirus B19 DNA in nine cases may be interpreted ambiguously. Pityriasis lichenoides et varioliformis acuta and group-A beta hemolytic streptococcal infection. English JC III, Collins M, Bryant-Bruce C. Int J Dermatol 1995; 34: 642–4. Biopsy-proven PLEVA in association with carriage of Gram-positive cocci cleared with ciprofloxacin in a 35-year-old woman. An identical eruption in her husband, who was found to have group A β-hemolytic streptococcus from a skin swab, cleared with erythromycin. Pityriasis lichenoides and acquired toxoplasmosis. Rongioletti F, Delmonte S, Rebora A. Int J Dermatol 1999; 38: 367–76. Biopsy-proven PLEVA in a patient with serology indicating acute toxoplasmosis failed to respond to azithromycin, but cleared with spiramycin followed by trimethoprim–sulfamethoxazole. First-line therapies Oral erythromycin C Pityriasis lichenoides in childhood: a retrospective review of 124 patients. Ersoy-Evans S, Greco MF, Mancini AJ, Subasi N, Paller AS. J Am Acad Dermatol 2007; 56: 205–10. This was a retrospective study of 124 children, 71 of whom had PLEVA. The disease was recurrent in 77%. Erythromycin was given to 79.7% of the affected children and 66.6% of these showed at least a partial response. Only gold members can continue reading. Log In or Register to continue Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window) Related Related posts: Cat scratch disease Hemangiomas Tinea capitis Necrolytic migratory erythema Nevoid basal cell carcinoma syndrome Rocky Mountain spotted fever and other rickettsial infections Stay updated, free articles. Join our Telegram channel Join Tags: Treatment of Skin Disease Comprehensive Therapeutic Strategies Aug 7, 2016 | Posted by admin in Dermatology | Comments Off on Pityriasis lichenoides et varioliformis acuta Full access? Get Clinical Tree